Key result
Aliskiren and valsartan significantly attenuated albuminuria, urinary nephrin excretion, and glomerulosclerosis in mice with diabetic nephropathy, with synergistic effects in dual therapy.
Why the study?
Does aliskiren or valsartan improve markers of diabetic nephropathy in a mouse model?
Does aliskiren or valsartan improve markers of diabetic nephropathy in a mouse model?
Aliskiren and valsartan demonstrate protective effects against diabetic kidney disease in a mouse model through multiple mechanisms including reduction of podocyte injury, inflammation, and ER stress.
Answers are grounded in this paper and cite their sources.
Supports dual blockade in mouse diabetic nephropathy models; leaves open clinical translation to human disease.
AIM: We investigated whether aliskiren, a direct renin inhibitor, provided protection in a model of diabetic nephropathy in mice and compared its protective effects to valsartan, an angiotensin II type 1 receptor blocker. MATERIALS AND METHODS: Hyperglycemia was induced with streptozotocin (STZ, 40 mg/kg/day × 5 days) injection in DBA/2J mice fed on a high fat diet. Mice were treated with either aliskiren (25 mg/kg/day) or valsartan (8 mg/kg/day) for 6 weeks. RESULTS: Aliskiren and/or valsartan treatment significantly attenuated albuminuria, urinary nephrin excretion and glomerulosclerosis. Aliskiren and/or valsartan prevented reduction of podocin and WT1 protein abundance in diabetic mice. Aliskiren and/or valsartan significantly prevented increased expression of profibrotic growth factors (TGFβ, CTGF and PAI-1), proinflammatory cytokines (MCP-1, TNFα and IL-1β), endoplasmic reticulum (ER) stress markers (CHOP and XBP-1) and lipid accumulation in the kidney of diabetic animals. Aliskiren showed similar efficacy compared to valsartan therapy and dual treatment in some aspects has synergistic protective effects. CONCLUSION: Our study indicates that aliskiren and/or valsartan protects against diabetic kidney disease through multiple mechanisms, including decreasing podocyte injury, activation of profibrotic growth factors and proinflammatory cytokines, ER stress and accumulation of lipids.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2014) studied Diabetic nephropathy. Aliskiren vs. Valsartan (8 mg/kg/day) or dual treatment was evaluated on Albuminuria, urinary nephrin excretion and glomerulosclerosis. Aliskiren and valsartan significantly attenuated albuminuria, urinary nephrin excretion, and glomerulosclerosis in mice with diabetic nephropathy, with synergistic effects in dual therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: